China SFDA Encourages Regulatory Consultations In New Communication Guidelines
This article was originally published in PharmAsia News
Executive Summary
China hopes strengthened communication with sponsors will spur innovation and new drug approvals.
You may also be interested in...
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.